AveXis Inc. (NASDAQ:AVXS)‘s stock had its “buy” rating restated by analysts at Jefferies Group in a research report issued on Monday.

The analysts wrote, “Analysts Offer Insights on Healthcare Companies: AveXis Inc (NASDAQ: AVXS), Cidara Therapeutics (NASDAQ: CDTX) and Eiger Biopharmaceuticals (NASDAQ: EIGR) | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=f3b5765983&wpp_id=460067’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Analysts Offer Insights on Healthcare Companies: AveXis Inc (NASDAQ: AVXS), Cidara Therapeutics (NASDAQ: CDTX) and Eiger Biopharmaceuticals (NASDAQ: EIGR)”

A number of other equities analysts have also commented on the stock. Zacks Investment Research raised shares of AveXis from a “hold” rating to a “buy” rating and set a $52.00 price objective for the company in a research note on Tuesday, October 25th. Bank of America Corp. started coverage on shares of AveXis in a research note on Friday, October 21st. They issued a “buy” rating for the company. Chardan Capital set a $85.00 price objective on shares of AveXis and gave the stock a “buy” rating in a research note on Wednesday, November 2nd. Stifel Nicolaus started coverage on shares of AveXis in a research note on Monday. They issued a “hold” rating and a $65.00 price objective for the company. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $80.00 price objective (up previously from $52.00) on shares of AveXis in a research note on Wednesday, November 2nd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. AveXis currently has an average rating of “Buy” and a consensus target price of $66.67.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

AveXis (NASDAQ:AVXS) opened at 67.35 on Monday. The firm’s market capitalization is $1.86 billion. AveXis has a one year low of $16.11 and a one year high of $70.00. The firm has a 50-day moving average price of $49.59 and a 200 day moving average price of $40.56.

AveXis (NASDAQ:AVXS) last issued its earnings results on Thursday, November 10th. The company reported ($0.87) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.69) by $0.18. Equities research analysts anticipate that AveXis will post ($3.21) earnings per share for the current year.

In related news, insider Paul B. Manning sold 289,855 shares of AveXis stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $34.50, for a total value of $9,999,997.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

A number of hedge funds and other institutional investors have recently made changes to their positions in AVXS. American International Group Inc. purchased a new position in shares of AveXis during the second quarter valued at approximately $106,000. Nationwide Fund Advisors purchased a new position in shares of AveXis during the second quarter valued at approximately $120,000. Rhumbline Advisers purchased a new position in shares of AveXis during the third quarter valued at approximately $209,000. TD Asset Management Inc. purchased a new position in shares of AveXis during the second quarter valued at approximately $259,000. Finally, Teachers Advisors Inc. increased its position in shares of AveXis by 74.1% in the second quarter. Teachers Advisors Inc. now owns 7,524 shares of the company’s stock valued at $286,000 after buying an additional 3,202 shares during the period. Hedge funds and other institutional investors own 56.38% of the company’s stock.

AveXis Company Profile

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

5 Day Chart for NASDAQ:AVXS

Receive News & Stock Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related stocks with our FREE daily email newsletter.